Item 7.01 Regulation FD Disclosure.

On August 1, 2022, Otonomy, Inc. issued a press release announcing results for its Phase 2 clinical trial of OTO-313 in patients with tinnitus. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

All of the information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.
Exhibit No.   Description

99.1            Press Release dated August 1, 2022

104           Cover page interactive data file (embedded within the inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses